Ovoca Bio PLC
LSE:OVB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Ovoca Bio PLC
Common Shares Outstanding
Ovoca Bio PLC
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ovoca Bio PLC
LSE:OVB
|
Common Shares Outstanding
€29.5m
|
CAGR 3-Years
3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
0%
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Common Shares Outstanding
$137.6m
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
0%
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Common Shares Outstanding
$61.4m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
2%
|
CAGR 10-Years
0%
|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Common Shares Outstanding
$97.2m
|
CAGR 3-Years
17%
|
CAGR 5-Years
11%
|
CAGR 10-Years
9%
|
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Common Shares Outstanding
$62m
|
CAGR 3-Years
6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Common Shares Outstanding
€16.2m
|
CAGR 3-Years
0%
|
CAGR 5-Years
2%
|
CAGR 10-Years
1%
|
|
Ovoca Bio PLC
Glance View
Ovoca Bio Plc is a clinical-stage biopharmaceutical company. The company is headquartered in Dublin, Dublin and currently employs 5 full-time employees. The firm is engaged in identifying and developing therapeutics targeting the treatment of female sexual dysfunction. The Company’s product BP101 is a synthetic peptide, administered through a nasal spray that is being developed for the treatment of female sexual dysfunction-hypoactive sexual desire disorder (HSDD). The Company’s subsidiaries include Silver Star Ltd, Bulun LLC, Magsel LLC, IVIX LLC and OVB (Australia) Pty Ltd. The firm operates in Ireland, the United Kingdom (UK) and Russia.
See Also
What is Ovoca Bio PLC's Common Shares Outstanding?
Common Shares Outstanding
29.5m
EUR
Based on the financial report for Dec 31, 2024, Ovoca Bio PLC's Common Shares Outstanding amounts to 29.5m EUR.
What is Ovoca Bio PLC's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 10Y
0%
Over the last year, the Common Shares Outstanding growth was 0%. The average annual Common Shares Outstanding growth rates for Ovoca Bio PLC have been 3% over the past three years , 2% over the past five years .
